1932

Abstract

The microenvironment of breast cancer hosts a dynamic cross talk between diverse players of the immune system. While cytotoxic immune cells are equipped to control tumor growth and metastasis, tumor-corrupted immunosuppressive immune cells strive to impair effective immunity and promote tumor progression. Of these, regulatory T cells (T), the gatekeepers of immune homeostasis, emerge as multifaceted players involved in breast cancer. Intriguingly, clinical observations suggest that blood and intratumoral T can have strong prognostic value, dictated by breast cancer subtype. Accordingly, emerging preclinical evidence shows that T occupy a central role in breast cancer initiation and progression and provide critical support to metastasis formation. Here, T are not only important for immune escape but also promote tumor progression independent of their immune regulatory capacity. Combining insights into T biology with advances made across the rapidly growing field of immuno-oncology is expected to set the stage for the design of more effective immunotherapy strategies.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-cancerbio-042920-104912
2021-03-04
2024-06-16
Loading full text...

Full text loading...

/deliver/fulltext/cancerbio/5/1/annurev-cancerbio-042920-104912.html?itemId=/content/journals/10.1146/annurev-cancerbio-042920-104912&mimeType=html&fmt=ahah

Literature Cited

  1. Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M et al. 2019. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann. Oncol. 30:3405–11
    [Google Scholar]
  2. Ahmadzadeh M, Pasetto A, Jia L, Deniger DC, Stevanović S et al. 2019. Tumor-infiltrating human CD4+ regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity. Sci. Immunol. 4:31eaao4310
    [Google Scholar]
  3. Akimova T, Zhang T, Negorev D, Singhal S, Stadanlick J et al. 2017. Human lung tumor FOXP3+ Tregs upregulate four “Treg-locking” transcription factors. JCI Insight 2:16e94075
    [Google Scholar]
  4. Allaoui R, Hagerling C, Desmond E, Warfvinge CF, Jirström K, Leandersson K 2017. Infiltration of γδ T cells, IL-17+ T cells and FoxP3+ T cells in human breast cancer. Cancer Biomarkers 20:4395–409
    [Google Scholar]
  5. Alonso R, Flament H, Lemoine S, Sedlik C, Bottasso E et al. 2018. Induction of anergic or regulatory tumor-specific CD4+ T cells in the tumor-draining lymph node. Nat. Commun. 9:2113
    [Google Scholar]
  6. Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L et al. 2017. Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity 46:4577–86
    [Google Scholar]
  7. Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C et al. 2018. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174:51293–308.e36
    [Google Scholar]
  8. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA 2001. CD4+CD25high regulatory cells in human peripheral blood. J. Immunol. 167:31245–53
    [Google Scholar]
  9. Barsheshet Y, Wildbaum G, Levy E, Vitenshtein A, Akinseye C et al. 2017. CCR8+FOXp3+ Treg cells as master drivers of immune regulation. PNAS 114:236086–91
    [Google Scholar]
  10. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF et al. 2006. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 24:345373–80
    [Google Scholar]
  11. Batlle E, Massagué J. 2019. Transforming growth factor-β signaling in immunity and cancer. Immunity 50:4924–40
    [Google Scholar]
  12. Bentzon N, Düring M, Rasmussen BB, Mouridsen H, Kroman N 2007. Prognostic effect of estrogen receptor status across age in primary breast cancer. Int. J. Cancer 122:51089–94
    [Google Scholar]
  13. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF et al. 2018. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24:5541–50
    [Google Scholar]
  14. Biragyn A, Bodogai M, Olkhanud PB, Denny-Brown SR, Puri N et al. 2013. Inhibition of lung metastasis by chemokine CCL17-mediated in vivo silencing of genes in CCR4+ Tregs. J. Immunother. 36:4258–67
    [Google Scholar]
  15. Blatner NR, Bonertz A, Beckhove P, Cheon EC, Krantz SB et al. 2010. In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. PNAS 107:146430–35
    [Google Scholar]
  16. Blomberg OS, Spagnuolo L, De Visser KE 2018. Immune regulation of metastasis: mechanistic insights and therapeutic opportunities. Dis. Model. Mech. 11:10dmm036236
    [Google Scholar]
  17. Bluestone JA, Bour-Jordan H, Cheng M, Anderson M 2015. T cells in the control of organ-specific autoimmunity. J. Clin. Investig. 125:62250–60
    [Google Scholar]
  18. Bos PD, Plitas G, Rudra D, Lee SY, Rudensky AY 2013. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J. Exp. Med. 210:112435–66
    [Google Scholar]
  19. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68:6394–424
    [Google Scholar]
  20. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB et al. 2001. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27:68–73
    [Google Scholar]
  21. Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hämmerling GJ 2015. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells. Nat. Immunol. 16:6609–17
    [Google Scholar]
  22. Chinen T, Kannan AK, Levine AG, Fan X, Klein U et al. 2016. An essential role for the IL-2 receptor in Treg cell function. Nat. Immunol. 17:111322–33
    [Google Scholar]
  23. Coe D, Begom S, Addey C, White M, Dyson J, Chai JG 2010. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol. Immunother. 59:91367–77
    [Google Scholar]
  24. Curotto de Lafaille MA, Lafaille JJ 2009. Natural and adaptive Foxp3+ regulatory T cells: more of the same or a division of labor. ? Immunity 30:5626–35
    [Google Scholar]
  25. Dalotto-Moreno T, Croci DO, Cerliani JP, Martinez-Allo VC, Dergan-Dylon S et al. 2013. Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res 73:31107–17
    [Google Scholar]
  26. De Mattos-Arruda L, Sammut SJ, Ross EM, Bashford-Rogers R, Greenstein E et al. 2019. The genomic and immune landscapes of lethal metastatic breast cancer. Cell Rep 27:92690–708.e10
    [Google Scholar]
  27. Decker T, Fischer G, Bücke W, Bücke P, Stotz F et al. 2012. Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer. J. Cancer Res. Clin. Oncol. 138:111945–50
    [Google Scholar]
  28. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D et al. 2009. CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16:291–102
    [Google Scholar]
  29. Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI et al. 2018. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 19:140–50
    [Google Scholar]
  30. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD et al. 2019. Breast cancer statistics, 2019. CA Cancer J. Clin. 69:6438–51
    [Google Scholar]
  31. DiDomenico J, Lamano JB, Oyon D, Li Y, Veliceasa D et al. 2018. The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma. OncoImmunology 7:7e1448329
    [Google Scholar]
  32. Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT et al. 2018. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res. Treat. 167:3671–86
    [Google Scholar]
  33. Emens LA, Cruz C, Eder JP, Braiteh F, Chung C et al. 2019. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol 5:174–82
    [Google Scholar]
  34. Esterházy D, Canesso MCC, Mesin L, Muller PA, de Castro TBR et al. 2019. Compartmentalized gut lymph node drainage dictates adaptive immune responses. Nature 569:7754126–30
    [Google Scholar]
  35. Faghih Z, Erfani N, Haghshenas MR, Safaei A, Talei A-R, Ghaderi A 2014. Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes. Immunol. Lett. 158:57–65
    [Google Scholar]
  36. Fontenot JD, Gavin MA, Rudensky AY 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4:33036
    [Google Scholar]
  37. Garner H, de Visser KE 2020. Immune crosstalk in cancer progression and metastatic spread: a complex conversation. Nat. Rev. Immunol. 20:8482–97
    [Google Scholar]
  38. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S et al. 2009. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69:52000–9
    [Google Scholar]
  39. Gómez-Cuadrado L, Tracey N, Ma R, Qian B, Brunton VG 2017. Mouse models of metastasis: progress and prospects. Dis. Model. Mech. 10:91061–74
    [Google Scholar]
  40. Goudin N, Chappert P, Mégret J, Gross DA, Rocha B, Azogui O 2016. Depletion of regulatory T cells induces high numbers of dendritic cells and unmasks a subset of anti-tumour CD8+CD11c+ PD-1lo effector T cells. PLOS ONE 11:6e0157822
    [Google Scholar]
  41. Gu Y, Liu Y, Fu L, Zhai L, Zhu J et al. 2019. Tumor-educated B cells selectively promote breast cancer lymph node metastasis by HSPA4-targeting IgG. Nat. Med. 25:2312–22
    [Google Scholar]
  42. Halvorsen EC, Franks SE, Wadsworth BJ, Harbourne BT, Cederberg RA et al. 2019. IL-33 increases ST2+ Tregs and promotes metastatic tumour growth in the lungs in an amphiregulin-dependent manner. OncoImmunology 8:2e1527497
    [Google Scholar]
  43. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:5646–74
    [Google Scholar]
  44. Hori S, Nomura T, Sakaguchi S 2003. Control of regulatory T cell development by the transcription factor Foxp3. . Science 299:56091057–61
    [Google Scholar]
  45. Horlock C, Stott B, Dyson PJ, Morishita M, Coombes RC et al. 2009. The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer. Br. J. Cancer 100:71061–67
    [Google Scholar]
  46. Huang AC, Orlowski RJ, Xu X, Mick R, George SM et al. 2019. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 25:3454–61
    [Google Scholar]
  47. Huang S, Wei P, Hwang‐Verslues WW, Kuo W, Jeng Y et al. 2017. TGF‐β1 secreted by Tregs in lymph nodes promotes breast cancer malignancy via up‐regulation of IL‐17RB. EMBO Mol. Med. 9:121660–80
    [Google Scholar]
  48. Hughes E, Lauder SN, Smart K, Bloom A, Scott J et al. 2020. Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion. Cancer Immunol. Immunother. 69:2063–73
    [Google Scholar]
  49. Jacobs JFM, Punt CJA, Lesterhuis WJ, Sutmuller RPM, Brouwer HMLH et al. 2010. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin. Cancer Res. 16:205067–78
    [Google Scholar]
  50. Jang JE, Hajdu CH, Liot C, Miller G, Dustin ML, Bar-Sagi D 2017. Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer. Cell Rep 20:3558–71
    [Google Scholar]
  51. Jiang D, Gao Z, Cai Z, Wang M, He J 2015. Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis. BMC Cancer 15:727
    [Google Scholar]
  52. Jordan MS, Boesteanu A, Reed AJ, Petrone AL, Holenbeck AE et al. 2001. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat. Immunol. 2:4301–6
    [Google Scholar]
  53. Josefowicz SZ, Lu L-F, Rudensky AY 2012a. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30:531–64
    [Google Scholar]
  54. Josefowicz SZ, Niec RE, Kim HY, Treuting P, Chinen T et al. 2012b. Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature 482:7385395–99
    [Google Scholar]
  55. Kalekar LA, Schmiel SE, Nandiwada SL, Lam WY, Barsness LO et al. 2016. CD4+ T cell anergy prevents autoimmunity and generates regulatory T cell precursors. Nat. Immunol. 17:3304–14
    [Google Scholar]
  56. Kamada T, Togashi Y, Tay C, Ha D, Sasaki A et al. 2019. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. PNAS 116:209999–10008
    [Google Scholar]
  57. Kanamori M, Nakatsukasa H, Okada M, Lu Q, Yoshimura A 2016. Induced regulatory T cells: their development, stability, and applications. Trends Immunol 37:11803–11
    [Google Scholar]
  58. Karavitis J, Hix LM, Shi YH, Schultz RF, Khazaie K, Zhang M 2012. Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration. PLOS ONE 7:9e46342
    [Google Scholar]
  59. Kersten K, de Visser KE, van Miltenburg MH, Jonkers J 2017. Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol. Med. 9:2137–53
    [Google Scholar]
  60. Kieback E, Hilgenberg E, Stervbo U, Lampropoulou V, Shen P et al. 2016. Thymus-derived regulatory T cells are positively selected on natural self-antigen through cognate interactions of high functional avidity. Immunity 44:51114–26
    [Google Scholar]
  61. Kim I, Sanchez K, McArthur HL, Page D 2019. Immunotherapy in triple-negative breast cancer: present and future. Curr. Breast Cancer Rep. 11:259–271
    [Google Scholar]
  62. Kim JM, Rasmussen JP, Rudensky AY 2007. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8:2191–97
    [Google Scholar]
  63. Kim ST, Jeong H, Woo OH, Seo JH, Kim A et al. 2013. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am. J. Clin. Oncol. 36:3224–31
    [Google Scholar]
  64. Kitamura T, Qian BZ, Pollard JW 2015. Immune cell promotion of metastasis. Nat. Rev. Immunol. 15:273–86
    [Google Scholar]
  65. Koizumi S, Ishikawa H. 2019. Transcriptional regulation of differentiation and functions of effector T regulatory cells. Cells 8:8939
    [Google Scholar]
  66. Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H et al. 2020. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat. Immunol. 21:1346–58
    [Google Scholar]
  67. Lahl K, Loddenkemper C, Drouin C, Freyer J, Arnason J et al. 2007. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J. Exp. Med. 204:157–63
    [Google Scholar]
  68. Lee S, Cho EY, Park YH, Ahn JS, Im YH 2013. Prognostic impact of FOXP3 expression in triple-negative breast cancer. Acta Oncol 52:173–81
    [Google Scholar]
  69. Lee W, Lee GR. 2018. Transcriptional regulation and development of regulatory T cells. Exp. Mol. Med. 50:e456
    [Google Scholar]
  70. Legoux FP, Lim J-B, Cauley AW, Dikiy S, Ertelt J et al. 2015. CD4+ T cell tolerance to tissue-restricted self antigens is mediated by antigen-specific regulatory T cells rather than deletion. Immunity 43:5896–908
    [Google Scholar]
  71. Leonard JD, Gilmore DC, Dileepan T, Jenkins MK, Adams EJ et al. 2017. Identification of natural regulatory T cell epitopes reveals convergence on a dominant autoantigen. Immunity 47:107–17.e8
    [Google Scholar]
  72. Liu C, Chikina M, Deshpande R, Menk AV, Wang T et al. 2019. Treg cells promote the SREBP1-dependent metabolic fitness of tumor-promoting macrophages via repression of CD8+ T cell-derived interferon-γ. Immunity 51:2381–97.e6
    [Google Scholar]
  73. Liu F, Lang R, Zhao J, Zhang X, Pringle GA et al. 2011. CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res. Treat. 130:2645–55
    [Google Scholar]
  74. Liu J, Blake SJ, Yong MCR, Harjunpää H, Ngiow SF et al. 2016. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov 6:121382–99
    [Google Scholar]
  75. Liu S, Foulkes WD, Leung S, Gao D, Lau S et al. 2014. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res 16:5432
    [Google Scholar]
  76. Liyanage UK, Moore TT, Joo H-G, Tanaka Y, Herrmann V et al. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169:52756–61
    [Google Scholar]
  77. Loebbermann J, Thornton H, Durant L, Sparwasser T, Webster KE et al. 2012. Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection. Mucosal Immunol 5:2161–72
    [Google Scholar]
  78. Lowther DE, Goods BA, Lucca LE, Lerner BA, Raddassi K et al. 2016. PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight 1:5e85935
    [Google Scholar]
  79. Loyher PL, Rochefort J, Baudesson De Chanville C, Hamon P, Lescaille G et al. 2016. CCR2 influences T regulatory cell migration to tumors and serves as a biomarker of cyclophosphamide sensitivity. Cancer Res 76:226483–94
    [Google Scholar]
  80. Lucca LE, Dominguez-Villar M. 2020. Modulation of regulatory T cell function and stability by co-inhibitory receptors. Nat. Rev. Immunol. 20:68093
    [Google Scholar]
  81. Maeda N, Yoshimura K, Yamamoto S, Kuramasu A, Inoue M et al. 2014. Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients. Ann. Surg. Oncol. 21:4546–54
    [Google Scholar]
  82. Magnuson AM, Kiner E, Ergun A, Park JS, Asinovski N et al. 2018. Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types. PNAS 115:45E10672–81
    [Google Scholar]
  83. Mahmoud SMA, Paish EC, Powe DG, MacMillan RD, Lee AHS et al. 2011. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res. Treat. 127:99–108
    [Google Scholar]
  84. Malhotra D, Linehan JL, Dileepan T, Lee YJ, Purtha WE et al. 2016. Tolerance is established in polyclonal CD4+ T cells by distinct mechanisms, according to self-peptide expression patterns. Nat. Immunol. 17:2187–95
    [Google Scholar]
  85. Marie JC, Letterio JJ, Gavin M, Rudensky AY 2005. TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J. Exp. Med. 201:71061–67
    [Google Scholar]
  86. Martinez LM, Robila V, Clark NM, Du W, Idowu MO et al. 2019. Regulatory T cells control the switch from in situ to invasive breast cancer. Front. Immunol. 10:1942
    [Google Scholar]
  87. Miragaia RJ, Gomes T, Chomka A, Jardine L, Riedel A et al. 2019. Single-cell transcriptomics of regulatory T cells reveals trajectories of tissue adaptation. Immunity 50:2493–504.e7
    [Google Scholar]
  88. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K et al. 2009. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30:6899–911
    [Google Scholar]
  89. Miyashita M, Sasano H, Tamaki K, Hirakawa H, Takahashi Y et al. 2015. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res 17:124
    [Google Scholar]
  90. Moran AE, Holzapfel KL, Xing Y, Cunningham NR, Maltzman JS et al. 2011. T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. J. Exp. Med. 208:61279–89
    [Google Scholar]
  91. Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC 2010. Regulatory T cells in cancer. Adv. Cancer Res. 107:57–117
    [Google Scholar]
  92. Nanda R, Chow LQM, Dees EC, Berger R, Gupta S et al. 2016. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J. Clin. Oncol. 34:212460–67
    [Google Scholar]
  93. Núñez NG, Boari JT, Ramos RN, Richer W, Cagnard N et al. 2020. Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients. Nat. Commun. 11:3272
    [Google Scholar]
  94. Olkhanud PB, Baatar D, Bodogai M, Hakim F, Gress R et al. 2009. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res 69:145996–6004
    [Google Scholar]
  95. Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R et al. 2011. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells. Cancer Res 71:103505–15
    [Google Scholar]
  96. Onda M, Kobayashi K, Pastan I 2019. Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity. PNAS 116:104575–82
    [Google Scholar]
  97. Özdemir BC, Sflomos G, Brisken C 2018. The challenges of modeling hormone receptor-positive breast cancer in mice. Endocr. Relat. Cancer 25:5319–30
    [Google Scholar]
  98. Papaioannou E, Sakellakis M, Melachrinou M, Tzoracoleftherakis E, Kalofonos H, Kourea E 2019. A standardized evaluation method for FOXP3+ Tregs and CD8+ T-cells in breast carcinoma: association with breast carcinoma subtypes, stage and prognosis. Anticancer Res 39:31217–32
    [Google Scholar]
  99. Peng GL, Li L, Guo YW, Yu P, Yin XJ et al. 2019. CD8+ cytotoxic and FoxP3+ regulatory T lymphocytes serve as prognostic factors in breast cancer. Am. J. Transl. Res. 11:85039–53
    [Google Scholar]
  100. Perez SA, Karamouzis MV, Skarlos DV, Ardavanis A, Sotiriadou NN et al. 2007. CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin. Cancer Res. 13:92714–21
    [Google Scholar]
  101. Planes-Laine G, Rochigneux P, Bertucci F, Chrétien AS, Viens P et al. 2019. PD-1/PD-L1 targeting in breast cancer: The first clinical evidences are emerging—a literature review. Cancers 11:7e1033
    [Google Scholar]
  102. Plitas G, Konopacki C, Wu K, Bos PD, Morrow M et al. 2016. Regulatory T cells exhibit distinct features in human breast cancer. Immunity 45:51122–34
    [Google Scholar]
  103. Plitas G, Rudensky AY. 2020. Regulatory T cells in cancer. Annu. Rev. Cancer Biol. 4:459–77
    [Google Scholar]
  104. Qiu SQ, Waaijer SJH, Zwager MC, de Vries EGE, van der Vegt B, Schröder CP 2018. Tumor-associated macrophages in breast cancer: innocent bystander or important player. ? Cancer Treat. Rev. 70:178–89
    [Google Scholar]
  105. Rech AJ, Mick R, Martin S, Recio A, Aqui NA et al. 2012. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci. Transl. Med. 4:134134ra62
    [Google Scholar]
  106. Roncador G, Brown PJ, Maestre L, Hue S, Martínez-Torrecuadrada JL et al. 2005. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur. J. Immunol. 35:61681–91
    [Google Scholar]
  107. Russell WL, Russell LB, Gower JS 1959. Exceptional inheritance of a sex-linked gene in the mouse explained on the basis that the X/O sex chromosome constitution is female. PNAS 45:4554–60
    [Google Scholar]
  108. Sakaguchi S, Yamaguchi T, Nomura T, Ono M 2008. Regulatory T cells and immune tolerance. Cell 133:5775–87
    [Google Scholar]
  109. Sawant DV, Yano H, Chikina M, Zhang Q, Liao M et al. 2019. Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion. Nat. Immunol. 20:6724–35
    [Google Scholar]
  110. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH et al. 2018. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379:222108–21
    [Google Scholar]
  111. Schreiber TH, Wolf D, Bodero M, Podack E 2012. Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination. OncoImmunology 1:5642–48
    [Google Scholar]
  112. Sektioglu IM, Carretero R, Bulbuc N, Bald T, Tüting T et al. 2017. Basophils promote tumor rejection via chemotaxis and infiltration of CD8+ T cells. Cancer Res 77:2291–302
    [Google Scholar]
  113. Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH et al. 2013. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br. J. Cancer 109:102705–13
    [Google Scholar]
  114. Sharma A, Rudra D. 2018. Emerging functions of regulatory T cells in tissue homeostasis. Front. Immunol. 9:883
    [Google Scholar]
  115. Soroosh P, Doherty TA, Duan W, Mehta AK, Choi H et al. 2013. Lung-resident tissue macrophages generate Foxp3+ regulatory T cells and promote airway tolerance. J. Exp. Med. 210:4775–88
    [Google Scholar]
  116. Su S, Liao J, Liu J, Huang D, He C et al. 2017. Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer. Cell Res 27:4461–82
    [Google Scholar]
  117. Sun S, Fei X, Mao Y, Wang X, Garfield DH et al. 2014. PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol. Immunother. 63:4395–406
    [Google Scholar]
  118. Syed Khaja AS, Toor SM, El Salhat H, Faour I, Ul Haq N et al. 2017. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. Oncotarget 8:2033159–71
    [Google Scholar]
  119. Szabo PA, Levitin HM, Miron M, Snyder ME, Senda T et al. 2019. Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease. Nat. Commun. 10:4706
    [Google Scholar]
  120. Szurek E, Cebula A, Wojciech L, Pietrzak M, Rempala G et al. 2015. Differences in expression level of helios and neuropilin-1 do not distinguish thymus-derived from extrathymically-induced CD4+Foxp3+ regulatory T cells. PLOS ONE 10:10e0141161
    [Google Scholar]
  121. Takenaka M, Seki N, Toh U, Hattori S, Kawahara A et al. 2013. FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. Mol. Clin. Oncol. 1:4625–32
    [Google Scholar]
  122. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ et al. 2011. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470:7335548–53
    [Google Scholar]
  123. Taylor NA, Vick SC, Iglesia MD, Brickey WJ, Midkiff BR et al. 2017. Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. J. Clin. Investig. 127:93472–83
    [Google Scholar]
  124. Togashi Y, Shitara K, Nishikawa H 2019. Regulatory T cells in cancer immunosuppression—implications for anticancer therapy. Nat. Rev. Clin. Oncol. 16:6356–71
    [Google Scholar]
  125. Tsang JYS, Hui SW, Ni YB, Chan SK, Yamaguchi R et al. 2014. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers. Breast Cancer Res. Treat. 143:1–9
    [Google Scholar]
  126. Vadrevu SK, Chintala NK, Sharma SK, Sharma P, Cleveland C et al. 2014. Complement C5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. Cancer Res 74:133454–65
    [Google Scholar]
  127. Vignali DAA, Collison LW, Workman CJ 2008. How regulatory T cells work. Nat. Rev. Immunol. 8:7523–32
    [Google Scholar]
  128. Villarreal DO, L'Huillier A, Armington S, Mottershead C, Filippova EV et al. 2018. Targeting CCR8 induces protective antitumor immunity and enhances vaccine-induced responses in colon cancer. Cancer Res 78:185340–48
    [Google Scholar]
  129. Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK et al. 2019. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat. Med. 25:6920–28
    [Google Scholar]
  130. Wang L, Simons DL, Lu X, Tu TY, Solomon S et al. 2019. Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer. Nat. Immunol. 20:91220–30
    [Google Scholar]
  131. Wang Y, Sun J, Qu X 2016. Regulatory T cells are an important prognostic factor in breast cancer: a systematic review and meta-analysis. Neoplasma 63:5789–98
    [Google Scholar]
  132. Wei SC, Duffy CR, Allison JP 2018. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8:91069–86
    [Google Scholar]
  133. Wellenstein MD, de Visser KE 2018. Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity 48:3399–416
    [Google Scholar]
  134. West NR, Kost SE, Martin SD, Milne K, deLeeuw RJ et al. 2013. Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br. J. Cancer 108:155–62
    [Google Scholar]
  135. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B 2003. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9:2606–12
    [Google Scholar]
  136. Yamaguchi T, Hirota K, Nagahama K, Ohkawa K, Takahashi T et al. 2007. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 27:1145–59
    [Google Scholar]
  137. Yan M, Jene N, Byrne D, Millar EK, O'Toole SA et al. 2011. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res 13:2R47
    [Google Scholar]
  138. Yano H, Andrews LP, Workman CJ, Vignali DAA 2019. Intratumoral regulatory T cells: markers, subsets and their impact on anti‐tumor immunity. Immunology 157:3232–47
    [Google Scholar]
  139. Zhang Y, Lazarus J, Steele NG, Yan W, Lee H-J et al. 2020. Regulatory T cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis. Cancer Discov 10:3422–39
    [Google Scholar]
  140. Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY 2010. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 463:7282808–12
    [Google Scholar]
  141. Zhou J, Li X, Wu X, Zhang T, Zhu Q et al. 2018. Exosomes released from tumor-associated macrophages transfer miRNAs that induce a Treg/Th17 cell imbalance in epithelial ovarian cancer. Cancer Immunol. Res. 6:121578–92
    [Google Scholar]
  142. Zhou Y, Shao N, Aierken N, Xie C, Ye R et al. 2017. Prognostic value of tumor-infiltrating Foxp3+ regulatory T cells in patients with breast cancer: a meta-analysis. J. Cancer 8:194098–105
    [Google Scholar]
/content/journals/10.1146/annurev-cancerbio-042920-104912
Loading
/content/journals/10.1146/annurev-cancerbio-042920-104912
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error